Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Clinical trial NCT05410041 · UNKNOWN

Trial details

NCT number: NCT05410041
Sponsor: Beijing Boren Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non Hodgkin Lymphoma

Start date: 2022-05-25
Primary completion: 2023-04-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.